A Double Blind, Randomized, Cross- Over Study Examining Efficacy Of Pf-06372865 In A Photosensitivity Epilepsy Study Using Lorazepam As A Positive Control

Trial Profile

A Double Blind, Randomized, Cross- Over Study Examining Efficacy Of Pf-06372865 In A Photosensitivity Epilepsy Study Using Lorazepam As A Positive Control

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Mar 2017

At a glance

  • Drugs PF 6372865 (Primary) ; Lorazepam
  • Indications Reflex epilepsy
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 13 Mar 2017 Status changed from recruiting to completed.
    • 18 Jan 2017 Planned End Date changed from 1 Jan 2017 to 1 Feb 2017.
    • 21 Dec 2016 Planned End Date changed from 1 Mar 2017 to 1 Jan 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top